Annual Drug Patent Expirations for LONSURF
Lonsurf is a drug marketed by Taiho Oncology and is included in one NDA. It is available from one supplier. There are six patents protecting this drug.
Drug patent litigation for LONSURF.
This drug has ninety-nine patent family members in thirty-three countries.
The generic ingredient in LONSURF is tipiracil hydrochloride; trifluridine. One supplier is listed for this compound. Additional details are available on the tipiracil hydrochloride; trifluridine profile page.
For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact admin@DrugPatentWatch.com or visit www.DrugPatentWatch.com
